WHO-conducted metanalysis [61] showed an increased risk of infection for patients treated with IL-6 receptor antagonists compared with those treated with SOC or placebo, and consistent results were disclosed by Han et al. [69] in a meta-analysis investigating infection risk during the use of IL-6 drugs. This evidence concerns the gene IL6 and infection.